Dr. Fleischmann has received consultant fees and/or research grants (less than $10,000 each) from Abbott, Amgen, Astellas, AstraZeneca, Biogen Idec, BMS, Genentech, HGS, Janssen, Lexicon, Lilly, MSD, Novartis, Pfizer, Roche, Sanofi-Aventis, and UCB Pharma.
Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study†
Article first published online: 26 JUN 2014
© 2014 The Authors. Arthritis Care & Research is published by Wiley Periodicals, Inc. on behalf of the American College of Rheumatology.
This is an open access article under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
Arthritis Care & Research
Volume 66, Issue 7, pages 1085–1092, July 2014
How to Cite
Gladman, D., Fleischmann, R., Coteur, G., Woltering, F. and Mease, P. J. (2014), Effect of Certolizumab Pegol on Multiple Facets of Psoriatic Arthritis as Reported by Patients: 24-Week Patient-Reported Outcome Results of a Phase III, Multicenter Study. Arthritis Care Res, 66: 1085–1092. doi: 10.1002/acr.22256
ClinicalTrials.gov identifier: NCT01087788.
- Issue published online: 26 JUN 2014
- Article first published online: 26 JUN 2014
- Accepted manuscript online: 10 DEC 2013 02:33PM EST
- Manuscript Accepted: 3 DEC 2013
- Manuscript Received: 12 JUL 2013
- UCB Pharma